Estudo Clínico Contra a Diabetes Tipo 2 Intratável (CAPTAIN-T2D) (CAPTAIN-T2D)
Estudo de Fase 2 com Clofutriben e Placebo contra Diabetes Tipo 2 Intratável (CAPTAIN-T2D)
CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
CAPTAIN-T2D is a two-part, multicenter, randomized, double-blind, parallel group, placebo- controlled trial of the 11-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor clofutriben. The primary objectives of this trial are to characterize the relationship of clofutriben dose to improved glycemic control, and to identify one or more doses suitable for Phase 3 evaluation, in patients with T2D and elevated cortisol.
The trial consists of two parts.
Part 1 (Screening) will last between approximately 5 to 9 weeks for most participants. The screening period duration allows for (sequentially) initial eligibility screen, dexamethasone suppression test, and further eligibility assessments.
During Part 2 (Treatment), participants will be randomized to placebo or one of four clofutriben doses. Part 2 will last 24 weeks with a follow-up phone call 4 weeks after the last dose of trial medication.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Arizona
-
Chandler, Arizona, Estados Unidos, 85225
- Recrutamento
- Arizona Clinical Trials - Pecos
-
Contato:
- Kamila Manager
- Número de telefone: 480-470-4000
- E-mail: kojeda@azclinicaltrials.com
-
Tucson, Arizona, Estados Unidos, 85711
- Recrutamento
- Arizona Clinical Trials - Broadway
-
Contato:
- Leanne Manager
- Número de telefone: 480-470-4000
- E-mail: lbuchenholz@azclinicaltrials.com
-
-
California
-
Fountain Valley, California, Estados Unidos, 92708
- Recrutamento
- Ark Clinical Research - Fountain Valley
-
Contato:
- Lizeth Manager
- Número de telefone: 323-588-1990
- E-mail: lsuncin@velocityclinical.com
-
Huntington Park, California, Estados Unidos, 90255
- Recrutamento
- Velocity Clinical Research, Huntington Park
-
Contato:
- Tim Manager
- Número de telefone: 5135799911
- E-mail: tpeterson@velocityclinical.com
-
La Mesa, California, Estados Unidos, 91942
- Recrutamento
- Velocity Clinical Research - Gardena
-
Contato:
- Tim Manager
- Número de telefone: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
Long Beach, California, Estados Unidos, 90815
- Recrutamento
- Ark Clinical Research - Long Beach
-
Contato:
- Mike Manager
- Número de telefone: 562-997-1000
- E-mail: mdelgado@arkclinicalresearch.com
-
Los Angeles, California, Estados Unidos, 90057
- Recrutamento
- Velocity Clinical Research, Los Angeles
-
Contato:
- Tim Manager
- Número de telefone: 5135799911
- E-mail: tpeterson@velocityclinical.com
-
Los Angeles, California, Estados Unidos, 90015
- Recrutamento
- Los Angeles Institute for Metabolic Research
-
Contato:
- Lourdes Manager
- Número de telefone: (213) 373-8380
- E-mail: lgaribay@metabolic.la
-
Northridge, California, Estados Unidos, 98433
- Recrutamento
- Amicis Research Center- Nordhoff
-
Contato:
- Veronica Clinical Research Manager
- Número de telefone: (818) 929-7774
- E-mail: veronica.macias@amicisresearch.com
-
San Diego, California, Estados Unidos, 92120
- Recrutamento
- Alliance Clinical San Diego
-
Contato:
- Sandra Manager
- Número de telefone: (858) 299-0009
- E-mail: SMisic@allianceclinicalnetwork.com
-
-
Florida
-
Edgewater, Florida, Estados Unidos, 32132
- Recrutamento
- Velocity Clinical Research, New Smyrna Beach
-
Contato:
- Tim Manager
- Número de telefone: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
Fort Lauderdale, Florida, Estados Unidos, 33312
- Recrutamento
- The Center for Diabetes and Endocrine Care
-
Contato:
- Marie Study Coordinator
- Número de telefone: ext 236 954-963-7191
- E-mail: mmartin@diabetes-endocare.com
-
Miami, Florida, Estados Unidos, 33173
- Recrutamento
- Admed Research LLC
-
Contato:
- Indiana Manager
- Número de telefone: 786-687-2882
- E-mail: igonzalez@admedresearch.com
-
New Port Richey, Florida, Estados Unidos, 34652
- Recrutamento
- Suncoast Clinical Research, Inc
-
Contato:
- Cathy Manager
- Número de telefone: 727-849-4131
- E-mail: cbarnes@suncoastclinicalresearch.com
-
Port Charlotte, Florida, Estados Unidos, 33952
- Recrutamento
- Innovative Research Institute
-
Contato:
- Lauren Manager
- Número de telefone: (+1) 2832276233
- E-mail: l.ellis@medpace.com
-
Port Orange, Florida, Estados Unidos, 32127
- Recrutamento
- Progressive Medical Research
-
Contato:
- Nora Clinical Research Manager
- Número de telefone: 3457 386-304-7070
- E-mail: norab@progressivemedicalresearch.com
-
Winter Park, Florida, Estados Unidos, 32789
- Recrutamento
- Conquest Research
-
Contato:
- Malisa Manager
- Número de telefone: 407-916-0060
- E-mail: malisa.agard@conquestresearch.com
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30303
- Recrutamento
- Emory University School of Medicine
-
Contato:
- Rohit Manager
- Número de telefone: 404-778-1695
- E-mail: rohit.parab@emory.edu
-
Columbus, Georgia, Estados Unidos, 31904
- Recrutamento
- IACT Health-Brookstone Centre Pkwy
-
Contato:
- kristina Manager
- Número de telefone: 706.321.0495
- E-mail: kristina.erb@centricityresearch.com
-
-
Idaho
-
Boise, Idaho, Estados Unidos, 83709
- Recrutamento
- Paradigm Clinical Research - Boise, ID
-
Contato:
- Janaie Manager
- Número de telefone: 208-801-7440
- E-mail: jbounsana@paradigm-research.com
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60607
- Recrutamento
- Chicago Clinical Research Institute
-
Contato:
- Manognya Clinical Research Manager
- Número de telefone: 303 3127913241
- E-mail: manognya@ccrii.us
-
-
Iowa
-
West Des Moines, Iowa, Estados Unidos, 50226
- Recrutamento
- Iowa Diabetes and Endocrinology Research Center
-
Contato:
- Crystal Manager
- Número de telefone: 515-207-7486
- E-mail: choffman@iderc.com
-
-
Kansas
-
Wichita, Kansas, Estados Unidos, 67226
- Recrutamento
- Alliance for Multispecialty Research - Wichita East
-
Contato:
- Terry Manager
- Número de telefone: 316-689-6635
- E-mail: terry.klein@amr-clinical.com
-
-
Kentucky
-
Edgewood, Kentucky, Estados Unidos, 41017
- Recrutamento
- St. Elizabeth Healthcare
-
Contato:
- Amber Manager
- Número de telefone: 859-655-1567
- E-mail: amber.avery@stelizabeth.com
-
-
Louisiana
-
Lafayette, Louisiana, Estados Unidos, 70508
- Recrutamento
- Velocity Clinical Research, Lafayette
-
Contato:
- Tim Manager
- Número de telefone: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
Metairie, Louisiana, Estados Unidos, 70006
- Recrutamento
- NOLA Care Clinical Research
-
Contato:
- Rosina Manager
- Número de telefone: 504-427-6324
- E-mail: rosinaducote@gmail.com
-
New Orleans, Louisiana, Estados Unidos, 70112
- Recrutamento
- Tulane University School of Medicine
-
Contato:
- Neha Manager
- Número de telefone: 5049889803
- E-mail: nupadhyay@tulane.edu
-
-
Maryland
-
Rockville, Maryland, Estados Unidos, 20854
- Recrutamento
- Velocity Clinical Research, Rockville
-
Contato:
- Tim Manager
- Número de telefone: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
-
Massachusetts
-
Springfield, Massachusetts, Estados Unidos, 011030
- Recrutamento
- Elixia SISU BHR - Springfield
-
Contato:
- Darlene Manager
- Número de telefone: 5617970336
- E-mail: darlene.djaba@empathxresearch.com
-
-
Michigan
-
Troy, Michigan, Estados Unidos, 48085
- Recrutamento
- Oakland Medical Research Center
-
Contato:
- Juliejo (Julie) Clinical Research Manager
- Número de telefone: 248-687-7412
- E-mail: juliejolafave@msn.com
-
-
Nebraska
-
Lincoln, Nebraska, Estados Unidos, 68510
- Recrutamento
- Velocity Clinical Research, Lincoln
-
Contato:
- Tim Manager
- Número de telefone: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
Omaha, Nebraska, Estados Unidos, 68134
- Recrutamento
- Velocity Clinical Research, Omaha
-
Contato:
- Tim Manager
- Número de telefone: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89148
- Recrutamento
- Palm Research Center, Inc.
-
Contato:
- Raffaela Manager
- Número de telefone: 702-736-5161
- E-mail: raffaela@palmresearchcenter.com
-
Las Vegas, Nevada, Estados Unidos, 89108
- Recrutamento
- Alliance Clinical - Las Vegas
-
Contato:
- Stephanie Manager
- Número de telefone: (702) 680-1500
- E-mail: sruvalcaba@allianceclinicalnetwork.com
-
-
New York
-
Albany, New York, Estados Unidos, 12203
- Recrutamento
- Albany Medical College
-
Contato:
- Mohammed Manager
- Número de telefone: 518-264-4462
- E-mail: ismailmoh@amc.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27514
- Recrutamento
- University of North Carolina at Chapel Hill
-
Contato:
- Jessica Manager
- Número de telefone: 984-974-3004
- E-mail: jessica_caffey@med.unc.edu
-
Greenville, North Carolina, Estados Unidos, 27834
- Recrutamento
- Physicians East
-
Contato:
- Kristen Manager
- Número de telefone: 252-413-6392
- E-mail: ktaylor@physicianseast.com
-
Morehead City, North Carolina, Estados Unidos, 28557
- Recrutamento
- Lucas Research Inc
-
Contato:
- Christina Manager
- Número de telefone: 252-222-5700
- E-mail: christina.tornes@centricityresearch.com
-
Wilmington, North Carolina, Estados Unidos, 28401
- Recrutamento
- PMG Research of Wilmington, LLC
-
Contato:
- Kevin Manager
- Número de telefone: 910.815.6108
- E-mail: cannon1099@me.com
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45219
- Recrutamento
- Velocity Clinical Research, Cincinnati, Mt. Auburn
-
Contato:
- Tim Manager
- Número de telefone: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
Cincinnati, Ohio, Estados Unidos, 45242
- Recrutamento
- Velocity Clinical Research - Cincinnati, Blue Ash
-
Contato:
- Tim Manager
- Número de telefone: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
Columbus, Ohio, Estados Unidos, 43201
- Recrutamento
- Endocrinology Associates, Inc
-
Contato:
- Edward Clinical Research Manager
- Número de telefone: 614-453-9999
- E-mail: ek@endocrinology-associates.com
-
Columbus, Ohio, Estados Unidos, 43215
- Recrutamento
- Remington Davis, Inc
-
Contato:
- Tsunami Clinical Research Manager
- Número de telefone: 614-487-2560
- E-mail: Tbrisco@remdavis.com
-
-
Oregon
-
Eugene, Oregon, Estados Unidos, 97404
- Recrutamento
- Willamette Valley Clinical Studies
-
Contato:
- Patricia Manager
- Número de telefone: 541-461-0132
- E-mail: drpatb@aol.com
-
-
Pennsylvania
-
West Chester, Pennsylvania, Estados Unidos, 19380
- Recrutamento
- Suburban Research Associates
-
Contato:
- Tom Manager
- Número de telefone: 610-891-9024
- E-mail: tfrancis@suburbanresearch.com
-
-
South Carolina
-
Anderson, South Carolina, Estados Unidos, 29621
- Recrutamento
- Velocity Clinical Research, Anderson
-
Contato:
- Tim Manager
- Número de telefone: (864) 965-0190
- E-mail: tpeterson@velocityclinical.com
-
Mt. Pleasant, South Carolina, Estados Unidos, 29464
- Recrutamento
- Accellacare Charleston
-
Contato:
- Dhruva Manager
- Número de telefone: (843) 849-1880
- E-mail: dhruva.patel@accellacare.com
-
-
Texas
-
Austin, Texas, Estados Unidos, 78759
- Recrutamento
- Velocity Clinical Research, Austin
-
Contato:
- Tim Manager
- Número de telefone: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
Dallas, Texas, Estados Unidos, 75230
- Recrutamento
- Velocity Clinical Research - Dallas
-
Contato:
- Tim Manager
- Número de telefone: (972) 566-8631
- E-mail: tpeterson@velocityclinical.com
-
Houston, Texas, Estados Unidos, 77040
- Recrutamento
- Juno Research, LLC
-
Contato:
- Lian manager
- Número de telefone: 713-779-5494
- E-mail: lian_ramos@junoresearch.us
-
Lampasas, Texas, Estados Unidos, 76550
- Recrutamento
- Radiance Clinical Research
-
Contato:
- Lauren Clinical Research Manager
- Número de telefone: 512-556-4130
- E-mail: lgarner@radianceclinical.com
-
Lewisville, Texas, Estados Unidos, 75057
- Recrutamento
- Alliance Clinical - Lewisville (Epic Clinical Research)
-
Contato:
- Jessica Manager
- Número de telefone: (469) 361-8007
- E-mail: jpowell@allianceclinicalnetwork.com
-
Mission, Texas, Estados Unidos, 78572
- Recrutamento
- Texas Valley Clinical Research - Mission, TX
-
Contato:
- Omar Manager
- Número de telefone: 9568887400
- E-mail: gonzalez.md@tvcrmission.com
-
Round Rock, Texas, Estados Unidos, 78681
- Recrutamento
- Texas Diabetes & Endocrinology, P.A. - Round Rock
-
Contato:
- Olivia Clinical Research Manager
- Número de telefone: 512-334-3505
- E-mail: knutty@tderesearch.com
-
San Antonio, Texas, Estados Unidos, 78229
- Recrutamento
- Diabetes & Glandular Disease Clinic, P.A.
-
Contato:
- Myriam Manager
- Número de telefone: 1532 210-614-8612
- E-mail: myriam.turner@dgdclinic.com
-
San Antonio, Texas, Estados Unidos, 78251
- Recrutamento
- Texas Valley Clinical Research - San Antonio TX
-
Contato:
- Diana Manager
- Número de telefone: 2105431990
- E-mail: diana@tvcrtrials.com
-
Seabrook, Texas, Estados Unidos, 77586
- Recrutamento
- Elevate Clinical Research
-
Contato:
- Olga Clinical Research Manager
- Número de telefone: 832-271-1598
- E-mail: olga.konshina@elevateclinical.com
-
Weslaco, Texas, Estados Unidos, 78596
- Recrutamento
- Texas Valley Clinical Research, LLC
-
Contato:
- Czarina Manager
- Número de telefone: 956-431-8090
- E-mail: czarina@tvcrtrials.com
-
-
Utah
-
West Jordan, Utah, Estados Unidos, 84088
- Recrutamento
- Velocity Clinical Research, Salt Lake City
-
Contato:
- Tim Clinical Research Manager
- Número de telefone: 5135799911
- E-mail: tpeterson@velocityclinical.com
-
-
Virginia
-
Suffolk, Virginia, Estados Unidos, 23435
- Recrutamento
- Velocity Clinical Research, Suffolk
-
Contato:
- Tim Manager
- Número de telefone: (757) 996-4200
- E-mail: tpeterson@velocityclinical.com
-
Vienna, Virginia, Estados Unidos, 22182
- Recrutamento
- Conquest Research
-
Contato:
- Henry Manager
- Número de telefone: 703-372-3268
- E-mail: Henry.Tran@conquestresearch.com
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
From Screening 1
-
Age at least 18 years.
-
HbA1c ≥7.5% documented within 3 months prior to Screening 1. (The historical HbA1c value must have been obtained after at least 2 months on the current [as of Screening 1] regimen).
-
Treatment with stable and adequate doses of ≥2 injectable or oral ADMs. (An ADM will be deemed stable if the dose has been the same for at least 3 months prior to Screening 1 and without change between Screening 1 and Day 1) (An ADM dose will be deemed adequate if it is at or above the maximal labelled dose, or a sub-maximal, but not starting, dose if limited by tolerability (confer with MM if less than half-maximal dose).
-
Adequate total daily insulin is defined as at least 0.3 units/kg/day. Insulin dose will be deemed stable with adjustments of up to 20% total daily dose during the 3 months prior to Screening 1 or between Screening 1 and Day 1.
-
Use of insulin pumps or insulin brand changes (e.g., due to insurance change or shortage) are to be discussed with the MM.
-
At least one of the following
- ≥3 stable and adequate ADMs;
- diabetes complication (retinopathy, nephropathy, neuropathy, atherosclerotic heart disease);
- hypertension requiring ≥2 adequately dosed AHMs;
- adequately dosed basal or basal plus prandial insulin in addition to at least 1 other ADM; and
- adequately dosed incretin agonist (a single or combination agent counts as one ADM) in addition to at least 1 other ADM;
- evidence or history of osteoporosis or non-traumatic fracture (e.g., vertebral body compression);
- or established diagnosis of a neoplastic (non-malignant) source of hypercortisolism and have failed, are ineligible for, or declined surgery.
-
At DST • Post-DST cortisol level >1.8 µg/dL and serum dexamethasone ≥140 ng/dL. Patients with an established diagnosis of neoplastic hypercortisolism do not require a DST.
At Screening 2
- HbA1c ≥7.5% at Screening 2. At Day 1
- No change in, or initiation of, medications for hypertension within 1 month prior to Day 1.
Exclusion Criteria:
-
New-onset diabetes (onset <1 year in the past).
-
Unwillingness to maintain with current glucose-lowering regimen during the trial.
-
Unwillingness to adjust, add, replace, or discontinue current or other glucose-lowering medications during the trial as directed by the investigator.
-
Unwillingness to comply with CGM or other trial procedures.
-
Investigator considers the patient will otherwise be unwilling or unable to complete the trial.
-
Night-shift worker or otherwise habitually awake from 23:00 to 07:00 h.
-
Evidence for significant hypoglycemia while on their current diabetic treatment regimen(This includes episodes of symptomatic Level 3 hypoglycemia requiring external assistance for recovery, or CGM-documented prolonged [>15 min] or repeated episodes of either Level 2 hypoglycemia leading to >1%, or Level 1 hypoglycemia leading to >4%, in "time below range" within 3 months prior to Screening 1 or between Screening 1 and Day 1).
-
Any of the following in medical history:
- Type 1 diabetes mellitus (T1D), latent autoimmune diabetes in adults (LADA), or familial forms of maturity-onset diabetes of the young (MODY);
- A hemoglobinopathy or other condition which may interfere with measurement of HbA1c (e.g., sickle cell disease HbSS or other variants HbEE thalassemia, hemolytic anemia, recent blood transfusion);
- Hypersensitivity or severe reaction to dexamethasone;
- Pheochromocytoma, or suspicion thereof;
- Anorexia, or other eating disorder;
- Glucocorticoid resistance;
- Multiple sclerosis;
- Significant hepatic impairment (e.g., Child-Pugh Class B or C);
- Idiopathic thrombocytopenic purpura;
- Untreated or inadequately controlled moderate-to-severe sleep apnea (apnea-hypopnea index ≥15). (Patients whose condition has been well controlled with Continuous Positive Airway Pressure (CPAP) use for at least 3 months prior to Screening 1 are not excluded. Patients with a STOP-BANG score 5-8 should be referred for a sleep study outside the trial and may rescreen if found not to have moderate-to-severe sleep apnea);
- Current alcohol consumption >14 units/week or >4 units in a single day for males, or >7 units/week or >3 units in a single day for females. (Patients with a CAGE score 2-4 should be evaluated further outside the trial and may be rescreened if found not to have an alcohol [or other substance] use disorder);
- Untreated or inadequately controlled major depressive disorder, generalized anxiety disorder, bipolar disorder, post-traumatic stress disorder, or schizophrenia.(Patients whose condition has been well controlled with stable medical therapy, or has been asymptomatic, for at least 3 months prior to Screening 1 are not excluded); or
- Any other medical condition (including malignancy) that is likely to interfere with trial assessments or the patient's ability to complete the trial.
- Any of the following in medication history:
- Any of the excluded medications listed in Section 6.9;
- Any investigational drug within 4 weeks or within less than five times the drug's half-life, whichever is longer, prior to Screening 1 or between Screening 1 and Day 1;
- Woman of childbearing potential (WOCBP) not willing to adhere to highly effective contraception or strict abstinence for the duration of the trial and for 90 days post completion/discontinuation; and
- Pregnancy (including a positive urine test) or current breast feeding.
From Screening 2
• Prior probability of undiagnosed endogenous Cushing syndrome based on either of:
- wo morning serum cortisol values after dexamethasone suppression >5.0 mcg/dL together with plasma dexamethasone >140 ng/mL; or
- a morning serum cortisol value after dexamethasone suppression >1.8 mcg/dL, together with plasma dexamethasone >140 ng/mL and any one of the following that is not attributable to an etiology other than endogenous Cushing's syndrome:
- supraclavicular/dorsocervical fat accumulation;
- irounding of the face (especially compared with prior photos);
- skin changes (violaceous striae, skin thinning, or excessive bruising);
- proximal muscle weakness on exam; or
- history of deep vein thrombosis/pulmonary embolism.
- Plans for, or medically unable to forego, treatment for endogenous Cushing syndrome or ACS within the next 8 months. (For clarity, patients with EnCS or ACS, not having such treatment plans, and medically able to forego treatment for 8 months may enroll if otherwise eligible).
- Severe, poorly controlled hypertension (mean systolic BP >160 mmHg or mean diastolic BP >100 mmHg) at Screening 2 or between Screening 2 and Day 1, including by at-home monitoring. (Such patients will be eligible to rescreen for Part 2 when they restore BP <160/100 mmHg for 1 month on a new stable medication regimen).
- Positive urine screen for recreational drugs (except tetrahydrocannabinol (THC)).
- Glomerular filtration rate (GFR) (determined using Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) <45 mL/min/1.73 m².
- Poorly controlled hyperthyroidism/hypothyroidism (confirmed by TSH or Free thyroxine [fT4]).
- Liver enzymes >3 × upper limit of normal (ULN) (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or bilirubin >1.5 × ULN.(excepting benign conditions such as Gilbert's)
- Known hypersensitivity to clofutriben or to any of the product
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Dose 1
clofutriben .2 mg oral tablet daily |
HSD-1 inhibitor
Outros nomes:
|
|
Experimental: Dose 2
clofutriben 2mg oral tablet daily |
HSD-1 inhibitor
Outros nomes:
|
|
Experimental: Dose 3
clofutriben 6mg oral tablet daily |
HSD-1 inhibitor
Outros nomes:
|
|
Experimental: Dose 4
clofutriben 12 mg oral tablet daily |
HSD-1 inhibitor
Outros nomes:
|
|
Comparador de Placebo: placebo
placebo control oral tablet daily |
Placebo |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage of patients with both morning serum cortisol >1.8 mg/dL and morning plasma dexamethasone >=140 ng/dL (single composite endpoint) after a single dexamethasone 1 mg dose taken the prior night.
Prazo: 8-10 hours after the dexamethasone 1 mg dose.
|
To assess prevalence in the trial population of morning cortisol non-suppression by a single dexamethasone 1 mg dose. |
8-10 hours after the dexamethasone 1 mg dose.
|
|
Glycated hemoglobin A1c (%) change from baseline to Week 24 by treatment.
Prazo: 24 weeks.
|
To assess glycated hemoglobin A1c (%) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks. |
24 weeks.
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Fasting plasma glucose (mmol/L) change from baseline to Week 24 by treatment.
Prazo: 24 weeks
|
To assess glucose (mmol/L) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks. |
24 weeks
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
To evaluate the safety of clofutriben in participants with T2D and EC.
Prazo: From enrollment until end of trial 9 month
|
Frequency of TEAEs (treatment-emergent adverse even) by clofutriben dose |
From enrollment until end of trial 9 month
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do Sistema Endócrino
- Neoplasias
- Doenças Metabólicas
- Distúrbios do Metabolismo da Glicose
- Diabetes Mellitus
- Síndromes Paraneoplásicas
- Doenças da Glândula Adrenal
- Hiperfunção Adrenocortical
- Síndromes Endócrinas Paraneoplásicas
- Doenças Nutricionais e Metabólicas
- Diabetes Mellitus, Tipo 2
- Síndrome de Cushing
- Síndrome de ACTH Ectópica
- ASP3662
Outros números de identificação do estudo
Outros números de identificação do estudo
- SPI-62-CL-2006
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .